- Shares of protein degradation biotech Kymera Therapeutics, Inc. (KYMR) are down some 40% from their January 3rd, 2022 close on little news, as the entire space has come under pressure.
- The reality of no revenue until at least 2026 has begun to set in despite its potentially paradigm-changing approach to treating disease.
- With its lead asset undergoing evaluation in patients for the first time beginning this quarter, two other assets entering the clinic and insider buying, Kymera merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Kymera Therapeutics: A First Take